跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

C-907

Supelco

氯硝西泮标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C15H10ClN3O3
CAS號碼:
1622-61-3
分子量：:
315.71
EC號碼:
200-659-6
MDL號碼:
MFCD00057746
分類程式碼代碼:
41116107
PubChem物質ID:
329775195
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

儲存溫度

−20°C

SMILES 字串

[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1

InChI

1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

InChI 密鑰

DGBIGWXXNGSACT-UHFFFAOYSA-N

基因資訊

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

尋找類似的產品？ 前往 產品比較指南

相關類別

一般說明

以Klonopin和Rivotril作为商品名出售的氯硝西泮是一种有效的长效苯二氮卓类药物，具有抗焦虑、抗惊厥、肌肉松弛和催眠作用。氯硝西泮是用于治疗癫痫的处方药。这款认证的Snap-N-Spike®溶液适合通过GC/MS或LC/MS应用用于法医分析、临床毒理学、尿液药物测试或疼痛处方监控。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

產品號碼
描述
訂價

A-915

7-氨基氯硝西泮标准液 溶液, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-916

7-氨基氯硝西泮标准液 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-917

7-Aminoclonazepam-d4 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-924

7-Aminoclonazepam-d4 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-033

8种苯二氮卓类混标 CRM 溶液, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-905

Benzodiazepine Internal Standard-3 solution, 0.5-1.0 mg/mL in acetonitrile, ampule of 1.0 mL, certified reference material, Cerilliant®

C-905

氯硝安定-D4 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-906

氯硝安定-d4 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-047

氟溴唑仑 溶液, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-159

Diclazepam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

M-197

甲氯西泮 溶液, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

M-198

甲氯西泮-D3 溶液, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-160

2-氯地西泮-D4 溶液, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

G Chouinard
The Journal of clinical psychiatry, 48 Suppl, 29-37 (1987-10-01)
This is a report on the efficacy of clonazepam in the treatment of acute mania. The advantages of clonazepam over standard neuroleptics are its rapidity of action, its lack of toxicity, and, particularly important, the fact that it does not
Shigeru Morishita
Human psychopharmacology, 24(3), 191-198 (2009-03-31)
Clonazepam, first used for seizure disorders, is now increasingly used to treat affective disorders. We summarize the use of clonazepam to improve the management of depression. Clonazepam is useful for treatment-resistant and/or protracted depression, as well as for acceleration of
Raffaele Ferri et al.
Sleep medicine, 14(1), 24-29 (2012-10-27)
To analyze the differences in sleep structure and nocturnal motor activity between drug-free REM sleep behavior disorder (RBD) patients and those under therapy with clonazepam, and to evaluate the long-term longitudinal changes under continued therapy with clonazepam. Fifty-seven consecutive iRBD
Stuart J McCarter et al.
Sleep medicine, 14(3), 237-242 (2013-01-29)
REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin
Taeko Sasai et al.
Parkinsonism & related disorders, 19(2), 153-157 (2012-09-20)
The clinical effectiveness of pramipexole (PPX), a candidate treatment for idiopathic rapid eye movement sleep behavior disorder (iRBD), varies among individuals. This study investigates factors associated with PPX effectiveness for treating RBD symptoms. Ninety-eight consecutive patients with RBD who had
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務